Table 1.
Baseline characteristics of participants by serious hypoglycemia
| Serious hypoglycemia |
|||
|---|---|---|---|
| No (n = 100) | Yes (n = 97) | P value | |
| Intensive treatment (%) | 21 | 74 | <0.01 |
| Age (years) | 60 ± 9 | 62 ± 9 | 0.1 |
| Non-Hispanic white (%) | 62 | 73 | 0.09 |
| Men (%) | 93 | 93 | 0.95 |
| History of hypertension (%) | 76 | 86 | 0.07 |
| Prior CVD (%) | 35 | 39 | 0.54 |
| Prior hypoglycemia (%) | 8 | 25 | 0.001 |
| Diabetes duration (years) | 11 ± 8 | 14 ± 8 | 0.01 |
| BMI (kg/m2) | 31.8 ± 4.1 | 30.8 ± 4.4 | 0.08 |
| HbA1c (%) | 9.4 ± 1.4 | 9.0 ± 1.3 | 0.05 |
| HbA1c (mmol/mol) | 79 ± 16 | 75 ± 15 | |
| C-peptide (ng/mL) | 0.9 ± 0.6 | 0.6 ± 0.4 | <0.01 |
| Systolic blood pressure (mmHg) | 135 ± 18 | 129 ± 15 | 0.01 |
| Diastolic blood pressure (mmHg) | 77 ± 10 | 74 ± 10 | 0.04 |
| Total cholesterol (mg/dL) | 181 ± 43 | 179 ± 37 | 0.963 |
| LDL cholesterol (mg/dL) | 105 ± 35 | 103 ± 29 | 0.76 |
| HDL cholesterol (mg/dL) | 34 ± 9 | 40 ± 12 | <0.01 |
| Triglycerides (mg/dL) | 183 (135–286) | 150 (113–194) | <0.01 |
| Creatinine (mg/dL) | 0.9 (0.8–1.1) | 1 (0.8–1.2) | 0.05 |
| Albumin-to-creatinine ratio (mg/g) | 18 (7–65) | 14 (4–42) | 0.11 |
| Baseline CAC score | 156 (9–895) | 299 (47–1,120) | 0.05 |
| Medication use (%) | |||
| Insulin | 46 | 69 | <0.01 |
| Antihypertensive | 87 | 93 | 0.17 |
| β-Blocker | 29 | 30 | 0.90 |
| Thiazolidinedione | 9 | 12 | 0.44 |
| Sulfonylurea | 64 | 46 | 0.01 |
| Statin | 56 | 67 | 0.11 |
Data are mean ± SD, median (25th–75th percentile), or percentages. Prior hypoglycemia denotes signs and symptoms of hypoglycemia or blood glucose levels <70 mg/dL (∼3.9 mmol/L) during the last 1.5 months before randomization.